Fundraising Fox

Predictive Oncology

Pittsburgh, US · Delaware corporation · 1 known investors

Find your way into Predictive Oncology

304 people in our graph share verified history with the Predictive Oncology team — schools, employers, funds. One of them is your warm intro.

Will Bruneunlockedknows Raymond Vennare · together at Case Western Reserve University
×7knows the team · via Case Western Reserve University
×3knows the team · via University of Pittsburgh
knows the team · via Duquesne University

Predictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.

Advanced ManufacturingAI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

JB
Josh BlacherinExecutive
RVRaymond Vennare
Raymond VennareinExecutiveRaymond Vennare is an executive and board director with over three decades of experience in biotechnology, including roles building and managing companies for institutional investors and research institutions. He has worked in company creation, technology commercialization, and business development.
CI
Carl I SchwartzExecutive
BMBob Myers
Bob MyersinExecutive
JK
Joshua KornbergExecutive
DJDavid Johnson
David JohnsoninDirector of Engineering2022–2024

Board

RK
Ricardo KoenigsbergerBoard director
VR
Veena RaoBoard director
CN
Chuck NuzumBoard director
MHMatthew Hawryluk
Matthew HawrylukinDirector, Board of DirectorsChief Business Officer at Prime Medicine
GS
Gregory S. St. Clair, Sr.Board director
DH
Dan HadleyBoard director

Investors · 1

Yorkville AdvisorsreportedMountainside

Reported raises · per SEC filings

Form D private placements

$275.9M disclosed across 15 rounds · 2014–2025

▶$50.8MraisedOct 2025 · 29 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew HawrylukDirector
  • Chuck NuzumDirector
  • Josh BlacherExecutive Officer
  • Shawn MatthewsDirector
  • Veena RaoDirector
  • Gregory S. St. Clair, Sr.Director
  • Raymond F. VennareExecutive Officer, Director
  • Thomas L. McLaughlinExecutive Officer
  • Dan HadleyDirector
Offering amount
$50.8M
Amount sold
$50.8M
Sales commissions
$2.5M
Placement agents
H. C. Wainwright & Co., LLC
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$173.3MraisedOct 2025 · 20 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Chuck NuzumDirector
  • Veena RaoDirector
  • Dan HadleyDirector
  • Gregory S. St. Clair, Sr.Director
  • Matthew HawrylukDirector
  • Raymond F. VennareExecutive Officer, Director
  • Josh BlacherExecutive Officer
  • Thomas L. McLaughlinExecutive Officer
  • Shawn MatthewsDirector
Offering amount
$173.3M
Amount sold
$173.3M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$413.1KraisedSep 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nancy Chung-WelchDirector
  • Dan HadleyDirector
  • Raymond F. BennareExecutive Officer, Director
  • Chuck NuzumDirector
  • Josh BlacherExecutive Officer
  • Veena RaoDirector
  • Matthew HawrylukDirector
  • Gregory S. St. Clair, Sr.Director
Offering amount
$413.1K
Amount sold
$413.1K
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedAug 2024 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Veena RaoDirector
  • Chuck NuzumDirector
  • Matthew HawrylukDirector
  • Josh BlacherExecutive Officer
  • Gregory S. St. Clair, Sr.Director
  • Dan HadleyDirector
  • Raymond VennareExecutive Officer, Director
  • Nancy Chung-WelchDirector
Offering amount
$2.2M
Amount sold
$2.2M
Sales commissions
$262.8K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedJun 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • J Melville EngleExecutive Officer, Director
  • Christina JenkinsDirector
  • Nancy Chung-WelchDirector
  • Daniel E HandleyDirector
  • Bob MyersExecutive Officer
  • Raymond VennareDirector
  • Chuck NuzumDirector
  • Gregory St. ClairDirector
Offering amount
$2.3M
Amount sold
$2.3M
Sales commissions
$195.7K
Placement agents
H.C. Wainwright & Co. LLC
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.6MraisedMar 2021 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carl I SchwartzExecutive Officer, Director
  • Bob MyersExecutive Officer
  • J Melville EngleDirector
  • Nancy Chung-WelchDirector
  • Daniel E HandleyDirector
  • Gregory S St. Clair Sr.Director
  • Chuck NuzumDirector
  • Richard L GabrielDirector
Offering amount
$17.6M
Amount sold
$17.6M
Sales commissions
$1.6M
Placement agents
H.C. Wainwright & Co. LLC
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.8MraisedMar 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard L GabrielDirector
  • Daniel E HandleyDirector
  • Gregory S St. Clair Sr.Director
  • Chuck NuzumDirector
  • Nancy Chung-WelchDirector
  • Carl I SchwartzExecutive Officer, Director
  • Bob MyersExecutive Officer
  • J Melville EngleDirector
Offering amount
$16.8M
Amount sold
$16.8M
Sales commissions
$951K
Placement agents
H.C. Wainwright & Co. LLC
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedJul 2020 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew P RedingDirector
  • Daniel E HandleyDirector
  • J Melville EngleDirector
  • Richard L GabrielDirector
  • Carl I SchwartzExecutive Officer, Director, Promoter
  • Bob MyersExecutive Officer
Offering amount
$1.8M
Amount sold
$1.8M
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Acquisitions · 1

Early investors' stakes continue via these deals
zPREDICTA

zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.

In the news

Predictive Oncology closes $343.5M funding rounds for ATH treasury - Cryptopolitancryptopolitan.com · Oct 2025Predictive Oncology raises $343.5 million to fund digital token strategy By Investing.cominvesting.com · Oct 2025Predictive Oncology raises $344 million in crypto-focused private placement By Investing.cominvesting.com · Sep 2025Predictive Oncology secures $10 million funding agreement for growth By Investing.cominvesting.com · Jul 2025

Frequently asked questions

What does Predictive Oncology do?
Predictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
Who are Predictive Oncology's investors?
Predictive Oncology's investors include Yorkville Advisors.
How much funding has Predictive Oncology raised?
Predictive Oncology has disclosed $275.9M raised across 15 rounds.
Where is Predictive Oncology headquartered?
Predictive Oncology is headquartered in Pittsburgh, US.